App-Quantinova.ai

Abstract – steroid induced hyperglycemia and diabetes on the haematology ward: are we getting it right? Re‐audit following initiation of JBDS‐IP guidelines and teaching

K. Lazarus - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Chronic Lymphocytic Leukemia

Hydrocortisone

The emotional and psychological impact of blood cancer in patients in England

R. Coron - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hematology-oncology disease

N/A

Managing patients with systemic mastocytosis with associated haematological neoplasm: UK single centre experience

C. Oni - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Essential thrombocythemia

Hydroxycarbamide

Prevalence of latent iron deficiency in early pregnancy in a tertiary care hospital in Sri Lanka

H. N. De Silva - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Anemia

N/A

Physician associate (PA) led myeloproliferative neoplasm (MPN) telephone clinics: is this the way forward to a revolutionised service?

M. Khalifa - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Myeloid neoplasms

N/A

Capillary glucose monitoring in haematology inpatients on glucocorticoids

P. Withanage - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Autoimmune hemolytic anemia

Glucocorticoid

A review of the use of rasburicase for tumour lysis syndrome at Nottingham University Hospitals NHS Trust

S. A. Kazmi - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Alpha-thalassemia myelodysplasia syndrome

Allopurinol

Unique differences in clinical presentation between JAK2 splanchnic vein thrombosis and WHO defined JAK2 myeloproliferative neoplasm

S. George - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Myeloid neoplasms

Hydroxycarbamide

The diagnostic yield of bone marrow biopsy in patients with liver failure

T. Ko Ko - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Myeloid neoplasms

Hydroxycarbamide

A review of a case series of post renal‐transplantation erythrocytosis, a study of aetiological factors and outcomes

A. Da Silva - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

End stage renal disease

Erythropoietin

Fertility preservation in male oncology patients – emergency sperm and spermatogonial stem cell retrieval

L. Micol - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

N/A

The efficacy and predictive value of primary care 2‐week wait referrals for suspected haematological cancer: quality evaluation of GP referrals and their outcomes

A. Jaiswal - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Symptom burden in immune thrombocytopenia (ITP): findings reported by UK patients and physicians from the ITP World Impact Survey (I‐WISh)

N. Cooper - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Immune thrombocytopenia

N/A

The clinical characteristics, diagnosis and management of patients with mastocytosis in a tertiary centre

K. Hoyles - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Mastocytosis, cutaneous

Ergocalciferol

An evaluation of double or triple positivity in JAK2 positive essential thrombocythaemia and primary myelofibrosis

P. Scott - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Essential thrombocythemia

N/A

An audit of tumour lysis syndrome prophylaxis in patients with haematological malignancies

A. Cairns - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Renal insufficiency

Allopurinol

Retrospective analysis of full blood counts and iron studies on patients diagnosed with bowel cancer

T. Ball - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Impact of stopping long‐term immunoglobulin therapy in haematological secondary antibody deficiency

S. Goddard - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Chronic Lymphocytic Leukemia

Intratect

UK Patient perceptions on the symptomatic and emotional burden of vaso‐occlusive crises resulting from Sickle cell disease

B. Inusa - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Sickle cell anemia

Epimorph

Updated results of a phase Ib/II randomised study: polatuzumab vedotin (Pola) plus bendamustine (B) and rituximab (R) in relapsed/refractory diffuse large B‐cell lymphoma (R/R DLBCL)

L. H. Sehn - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Diffuse large B-cell lymphoma

Polatuzumab vedotin

Filters

45280 Abstracts